Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?
Adriano Venditti, Robert Peter Gale, Francesco Buccisano, Gert J. Ossenkoppele
Topics & Concepts
Myeloid leukemiaMedicineMinimal residual diseaseComplete remissionLeukemiaInternal medicineDiseaseOncologyHematologyResidualChemotherapyComputer scienceAlgorithmAcute Myeloid Leukemia ResearchHematopoietic Stem Cell TransplantationBone and Joint Diseases